The Role of Neuregulin in Human Cardiac Remodeling and Heart Failure

神经调节蛋白在人类心脏重塑和心力衰竭中的作用

基本信息

  • 批准号:
    8695440
  • 负责人:
  • 金额:
    $ 13.97万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-07-01 至 2015-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Dr. Ky is an adult cardiologist with advanced training in echocardiography and heart failure who is currently enrolled in the Master of Science in Epidemiology program at the University of Pennsylvania. Her long-term goal is to be an independent, patient-oriented physician scientist who will make significant contributions to the study of human cardiac remodeling and cardiovascular medicine. Her career development plan encompasses focused didactic coursework; first hand experience in patient-oriented research through the design and execution of a prospective cohort study and additional cohorts initiated by the candidate; advanced methods in epidemiology and biostatistics for use in two large prospective cohort studies; and a highly structured, cohesive mentoring program. The overall objective of this scientific proposal is to determine the clinical relevance of circulating neuregulin as it relates to ventricular remodeling and risk of adverse clinical outcomes across a broad range of human cardiac remodeling phenotypes. Basic science research has defined this pathway as critical in the maintenance of cardiac function, but whether these findings translate to humans is unknown. Preliminary evidence from the Penn Heart Failure Study (PHFS) suggests that circulating neuregulin-12 (NRG-12) levels may be independently predictive of future risk of death or cardiac transplantation, and this risk may differ significantly by heart failure etiology and severity. Under the direction of Primary mentor Dr. Stephen Kimmel and Co-mentor Dr. Thomas Cappola, Dr. Ky will definitively determine if NRG-12 is associated with clinical outcomes across different etiologies and severity of heart failure and quantify the relationship between NRG-12 and cardiac remodeling over time using two large prospective cohorts: PHFS and the Chronic Renal Insufficiency Cohort (CRIC). Together these cohorts span the entire spectrum of cardiac remodeling, with eccentric hypertrophy in PHFS, and all remodeling geometries, including normal and concentric hypertrophy, in CRIC. The aims of this proposal are to: 1) establish the strength and consistency of the relationship between NRG-12 levels and incident adverse cardiac outcomes in all PHFS patients with eccentric hypertrophy, stratified by etiology and severity; 2) determine the longitudinal relationship between NRG-12 and cardiac remodeling in CRIC; 3) determine the relationship between NRG-12 and incident cardiac outcomes in CRIC. This research will provide the first large scale, systematic data on circulating neuregulin in human heart disease, laying the foundation for this candidate's long-term goal of translating knowledge from basic science and clinical observations into new approaches to prevent and treat heart failure. The combination of advanced epidemiologic and biostatistical training and mentored, patient-oriented research will ensure Dr. Ky emerges as a highly successful independent investigator in translational cardiovascular research.
简介(申请人提供):Ky博士是一名成年心脏病专家,接受过超声心动图和心力衰竭方面的高级培训,目前在宾夕法尼亚大学攻读流行病学理学硕士课程。她的长期目标是成为一名独立的、以患者为导向的内科科学家,为人类心脏重塑和心血管医学的研究做出重大贡献。她的职业发展计划包括有重点的教学课程;通过设计和执行前瞻性队列研究和候选人发起的额外队列,在以患者为导向的研究方面的第一手经验;用于两个大型前瞻性队列研究的流行病学和生物统计学的先进方法;以及高度结构化和连贯的指导计划。这项科学建议的总体目标是确定循环中性调节蛋白的临床相关性,因为它与广泛的人类心脏重构表型的心室重构和不良临床结果的风险有关。基础科学研究已经将这一途径定义为维持心脏功能的关键,但这些发现是否适用于人类尚不清楚。来自宾夕法尼亚大学心力衰竭研究(PHFS)的初步证据表明,循环中的中性调节蛋白-12(NRG-12)水平可能独立地预测未来死亡或心脏移植的风险,并且这种风险可能因心力衰竭的病因和严重程度而显著不同。在初级导师Stephen Kimmel博士和共同导师Thomas Cappola博士的指导下,Ky博士将利用两个大型前瞻性队列:PHFS和慢性肾功能不全队列(CRIC),最终确定NRG-12是否与不同病因和心力衰竭严重程度的临床结局有关,并通过两个大型前瞻性队列来量化NRG-12与心脏重构的关系。这些队列一起跨越了心脏重构的整个范围,包括PHFS的偏心性肥厚,以及CRIC的所有重构几何图形,包括正常和向心性肥厚。这项建议的目的是:1)根据病因和严重程度分层,建立所有PHFS偏心性肥厚患者NRG-12水平与发生不良心脏结局关系的强度和一致性;2)确定NRG-12与CRIC心脏重构的纵向关系;3)确定NRG-12与CRIC发生心脏结局的关系。这项研究将提供有关人类心脏病中循环神经调节蛋白的第一个大规模、系统的数据,为这位候选人将基础科学和临床观察中的知识转化为预防和治疗心力衰竭的新方法的长期目标奠定基础。先进的流行病学和生物统计学培训与有指导、以患者为导向的研究相结合,将确保Ky博士在心血管转化性研究中成为一名非常成功的独立研究员。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.
  • DOI:
    10.1161/circimaging.112.973321
  • 发表时间:
    2012-09-01
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Sawaya H;Sebag IA;Plana JC;Januzzi JL;Ky B;Tan TC;Cohen V;Banchs J;Carver JR;Wiegers SE;Martin RP;Picard MH;Gerszten RE;Halpern EF;Passeri J;Kuter I;Scherrer-Crosbie M
  • 通讯作者:
    Scherrer-Crosbie M
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bonnie Ky其他文献

Bonnie Ky的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bonnie Ky', 18)}}的其他基金

MENTORING IN PATIENT-ORIENTED RESEARCH IN DEEP PHENOTYPING IN CARDIO-ONCOLOGY
指导心脏肿瘤学中以患者为导向的深度表型研究
  • 批准号:
    10745438
  • 财政年份:
    2023
  • 资助金额:
    $ 13.97万
  • 项目类别:
Long Term Effects of Breast Cancer Therapy on Cardiac Remodeling and Function
乳腺癌治疗对心脏重塑和功能的长期影响
  • 批准号:
    10475641
  • 财政年份:
    2021
  • 资助金额:
    $ 13.97万
  • 项目类别:
Long Term Effects of Breast Cancer Therapy on Cardiac Remodeling and Function
乳腺癌治疗对心脏重塑和功能的长期影响
  • 批准号:
    10202939
  • 财政年份:
    2021
  • 资助金额:
    $ 13.97万
  • 项目类别:
Mechanistic Risk Prediction of Radiation Therapy Cardiotoxicity
放射治疗心脏毒性的机制风险预测
  • 批准号:
    10217238
  • 财政年份:
    2020
  • 资助金额:
    $ 13.97万
  • 项目类别:
The Feasibility of a Biomarker Guided Strategy in Anthracycline Cardiotoxicity
生物标志物引导策略治疗蒽环类药物心脏毒性的可行性
  • 批准号:
    10219355
  • 财政年份:
    2020
  • 资助金额:
    $ 13.97万
  • 项目类别:
Mechanistic Risk Prediction of Radiation Therapy Cardiotoxicity
放射治疗心脏毒性的机制风险预测
  • 批准号:
    10442397
  • 财政年份:
    2020
  • 资助金额:
    $ 13.97万
  • 项目类别:
Mechanistic Risk Prediction of Radiation Therapy Cardiotoxicity
放射治疗心脏毒性的机制风险预测
  • 批准号:
    10658987
  • 财政年份:
    2020
  • 资助金额:
    $ 13.97万
  • 项目类别:
Multimarker Risk Prediction in Cancer Therapy Cardiotoxicity
癌症治疗心脏毒性中的多标志物风险预测
  • 批准号:
    8815198
  • 财政年份:
    2014
  • 资助金额:
    $ 13.97万
  • 项目类别:
The Role of Neuregulin in Human Cardiac Remodeling and Heart Failure
神经调节蛋白在人类心脏重塑和心力衰竭中的作用
  • 批准号:
    8035937
  • 财政年份:
    2010
  • 资助金额:
    $ 13.97万
  • 项目类别:
The Role of Neuregulin in Human Cardiac Remodeling and Heart Failure
神经调节蛋白在人类心脏重塑和心力衰竭中的作用
  • 批准号:
    8287170
  • 财政年份:
    2010
  • 资助金额:
    $ 13.97万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 13.97万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 13.97万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 13.97万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 13.97万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 13.97万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 13.97万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 13.97万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 13.97万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 13.97万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 13.97万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了